vs
Side-by-side financial comparison of NPK International Inc. (NPKI) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
NPK International Inc. is the larger business by last-quarter revenue ($75.2M vs $70.6M, roughly 1.1× Viridian Therapeutics, Inc.\DE). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 30.7%). NPK International Inc. produced more free cash flow last quarter ($5.8M vs $-84.7M).
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
NPKI vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.2M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | 37.7% | — |
| Operating Margin | 16.7% | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | 30.7% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $0.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.2M | — | ||
| Q3 25 | $68.8M | $70.6M | ||
| Q2 25 | $68.2M | — | ||
| Q1 25 | $64.8M | — | ||
| Q4 24 | $57.5M | — | ||
| Q3 24 | $44.2M | — | ||
| Q2 24 | $66.8M | — | ||
| Q1 24 | $49.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | $5.7M | $-34.6M | ||
| Q2 25 | $8.7M | — | ||
| Q1 25 | $10.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-174.3M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $7.3M | — |
| Q4 25 | 37.7% | — | ||
| Q3 25 | 31.9% | — | ||
| Q2 25 | 36.9% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 39.2% | — | ||
| Q3 24 | 27.5% | — | ||
| Q2 24 | 37.2% | — | ||
| Q1 24 | 36.0% | — |
| Q4 25 | 16.7% | — | ||
| Q3 25 | 13.2% | -56.7% | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 20.9% | — | ||
| Q4 24 | 20.2% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 18.7% | — | ||
| Q1 24 | 14.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.2% | -49.0% | ||
| Q2 25 | 12.7% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -394.3% | — | ||
| Q2 24 | 12.0% | — | ||
| Q1 24 | 14.9% | — |
| Q4 25 | $0.17 | — | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $0.10 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $-1.99 | — | ||
| Q2 24 | $0.09 | — | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $490.9M |
| Total DebtLower is stronger | $16.9M | — |
| Stockholders' EquityBook value | $351.2M | $503.0M |
| Total Assets | $441.8M | $577.1M |
| Debt / EquityLower = less leverage | 0.05× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | — | ||
| Q3 25 | $35.6M | $490.9M | ||
| Q2 25 | $26.0M | — | ||
| Q1 25 | $20.8M | — | ||
| Q4 24 | $17.8M | — | ||
| Q3 24 | $42.9M | — | ||
| Q2 24 | $35.1M | — | ||
| Q1 24 | $37.7M | — |
| Q4 25 | $16.9M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $8.1M | — | ||
| Q4 24 | $7.7M | — | ||
| Q3 24 | $14.0M | — | ||
| Q2 24 | $58.0M | — | ||
| Q1 24 | $77.4M | — |
| Q4 25 | $351.2M | — | ||
| Q3 25 | $333.9M | $503.0M | ||
| Q2 25 | $328.8M | — | ||
| Q1 25 | $326.9M | — | ||
| Q4 24 | $326.5M | — | ||
| Q3 24 | $316.5M | — | ||
| Q2 24 | $426.6M | — | ||
| Q1 24 | $421.6M | — |
| Q4 25 | $441.8M | — | ||
| Q3 25 | $404.5M | $577.1M | ||
| Q2 25 | $393.7M | — | ||
| Q1 25 | $390.0M | — | ||
| Q4 24 | $393.7M | — | ||
| Q3 24 | $389.6M | — | ||
| Q2 24 | $624.8M | — | ||
| Q1 24 | $640.8M | — |
| Q4 25 | 0.05× | — | ||
| Q3 25 | 0.03× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.18× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.0M | $-84.6M |
| Free Cash FlowOCF − Capex | $5.8M | $-84.7M |
| FCF MarginFCF / Revenue | 7.6% | -120.1% |
| Capex IntensityCapex / Revenue | 16.3% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $26.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.0M | — | ||
| Q3 25 | $24.7M | $-84.6M | ||
| Q2 25 | $21.4M | — | ||
| Q1 25 | $8.8M | — | ||
| Q4 24 | $-4.1M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | $11.9M | — |
| Q4 25 | $5.8M | — | ||
| Q3 25 | $12.0M | $-84.7M | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q4 24 | $-17.7M | — | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $21.0M | — | ||
| Q1 24 | $-1.9M | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 17.4% | -120.1% | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | -1.8% | — | ||
| Q4 24 | -30.8% | — | ||
| Q3 24 | -15.2% | — | ||
| Q2 24 | 31.4% | — | ||
| Q1 24 | -3.9% | — |
| Q4 25 | 16.3% | — | ||
| Q3 25 | 18.5% | 0.2% | ||
| Q2 25 | 17.1% | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 23.6% | — | ||
| Q3 24 | 21.4% | — | ||
| Q2 24 | 9.9% | — | ||
| Q1 24 | 28.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 4.37× | — | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 0.88× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.43× | — | ||
| Q1 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NPKI
| Rental Revenue | $34.8M | 46% |
| Products | $25.5M | 34% |
| Services | $14.9M | 20% |
VRDN
Segment breakdown not available.
